Trial Profile
Ibrutinib in Chronic Lymphocytic Leukaemia: a Single Centre Experience
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Expanded access; Therapeutic Use
- Sponsors Janssen Pharmaceuticals; Johnson & Johnson Innovative Medicine
- 04 Aug 2015 New trial record
- 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.